The National Institute on Drug Abuse (NIDA)

In a 🆕 commentary in 𝘈𝘯𝘯𝘢𝘭𝘴 𝘰𝘧 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘭 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦, The National Institutes of Health and FDA leaders call for innovation in development of smoking cessation treatments. The commentary emphasizes that engagement across stakeholders is critical to accelerate smoking cessation and reduce smoking-related disease and death. https://go.nih.gov/AztlR93

📣📆 Save the Date: Exciting Webinar Alert! Don’t miss our next webinar for Substance Use Prevention Month! Join our Communities Talk team for ""States Telling Their Prevention Story"" on Wednesday, October 30, 2024, from 3–4 p.m. ET! Explore impactful initiatives and learn how states are making significant strides in substance use prevention. You'll hear from CAPT Christopher Jones, Director of CSAP, along with prevention leaders from Maine and South Carolina and representatives from the National Association of State Alcohol and Drug Agency Directors (NASADAD) and the National Prevention Network (NPN). 👉 Register today to gain new insights and discover the transformative power of sharing your prevention story! https://lnkd.in/gk2BbKiT

Drug use and addiction research professionals: Join #NIDA for a virtual Workshop on Geospatial Data Science on December 3, 2024, from 12-4 PM ET! Explore how to harness the power of geospatial data science to advance understanding of the epidemiology, prevention, and treatment of drug use and addiction. Discussion Topics: ▪️ How are researchers currently applying geospatial data science in drug use and addiction research? ▪️ What advancements will be helpful to apply geospatial data science? ▪️ How are the results from the geospatial data science work being adopted or translated into real-world settings? ▪️ What are some challenges and barriers with applying geospatial data science? Are there any unique challenges with drug use and addiction research? Register today to attend: https://go.nih.gov/ISzCqFm 💻

#TakeBackDay collection sites are NOW OPEN nationwide! Help your community stay safe by cleaning out your medicine cabinet and taking back expired, unused, or unwanted meds for safe disposal! Find a collection site near you: https://lnkd.in/gRzMnm7U

With simple changes in language, harmful stigma and negativity around substance use disorder can be reduced or avoided. Learn what stigma is, how it affects people with a substance use disorder, and how you can help make a change: https://go.nih.gov/MduHoiP #NationalHealthEducationWeek #NHEW

🚨 Calling all researchers using #ABCDStudy data! 🚨Reminder to submit your abstract for the ABCD Insights & Innovations Meeting on March 3-4, 2025 by 12 AM ET, Nov. 1. Don’t miss your chance to present & learn from top experts in the field! 🧠✨ ABCDStudy.org/meeting

You may have seen news stories this week about “pink cocaine” (or “tusi”). What do researchers know about this emerging drug so far, and what should the public be aware of? Read below ⬇ Despite its name, “pink cocaine” rarely contains cocaine. It's a mixture of synthetic drugs in which ketamine and drugs like MDMA, meth, and opioids, have been detected. Read more in a NIDA-supported article from NYU Grossman School of Medicine: https://lnkd.in/eFwZDuJX As with other emerging drugs, the mixture of drugs in “pink cocaine” varies greatly, which can lead to unpredictable health effects. Taking a mixture of drugs can also increase potential health risks. Learn more about the effects of emerging drugs: https://lnkd.in/egkiZ3cK Through programs like the National Drug Early Warning System (NDEWS), NIDA supports research to track the emergence of new drugs to help inform researchers, medical professionals, policymakers, and the public. Learn more: https://lnkd.in/eHaXJGMH #NIH

This #TreatmentWeek, explore insights on opioid use disorder treatment. Research shows that higher doses of buprenorphine may improve recovery outcomes for people with opioid use disorder. Access to effective treatment options is critical for saving lives. https://go.nih.gov/uw7ik5y

A 🆕 #NIDA-funded study, based on data from Canada, found that #methadone outperforms #buprenorphine in helping people with opioid use disorder stay in treatment, which can be lifesaving. https://loom.ly/jngOUK4 Simon Fraser University JAMA Methadone was the first medication approved to treat opioid use disorder in the U.S. and is still one of the most effective. It is also the most used and most studied opioid use disorder medication in the world. Yet, in the United States, people with opioid use disorder continue to face many barriers in accessing methadone. These findings add to the evidence that greater access to methadone is needed to address the overdose crisis. For more information, read NIDA director Dr. Nora Volkow’s recent blog post: https://go.nih.gov/mmKECrA

🆕 #NIDA-funded research in 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘚𝘶𝘣𝘴𝘵𝘢𝘯𝘤𝘦 𝘜𝘴𝘦 𝘢𝘯𝘥 𝘈𝘥𝘥𝘪𝘤𝘵𝘪𝘰𝘯 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵: A community-academic partnership to develop an implementation support package for overdose prevention in permanent supportive housing. NYU Grossman School of Medicine https://lnkd.in/ghrvxKhN